Response to Kang et al.

We are glad to learn that Kang et al (1) have successfully replicated our findings, confirming that a profile of DNA methylation in CAR-T cells (termed EPICART signature in our case) is enriched in naïve T-cell subsets that are likely associated with improved clinical response in B-cell malignancies.Interestingly, the confirmation of our data occurs despite these authors did not use the authentic EPICART signature that we obtained using a rigorously trained, supervised classification model based on ridge-regularized logistic regression to accurately predict clinical response; instead Kang et al (1) used a basic hierarchical clustering (hereafter denominated PseudoEpicart).It is noteworthy that the PseudoEpicart